Avian Infectious coryza, a highly opportunistic respiratory tract infection caused by Avibacterium paragallinarum is now believed to be evolving as a re-emerging disease of poultry birds. Albeit adoption of strong precautionary/prophylactic measures i.e. vaccine/vaccination practice, the infection continues as complicated pattern of disease course worldwide that results in massive economic and production losses. India, being a major admirer of poultry products suffers tremendously with this insidious infectious insult every year, thus strives for some better optional measures to curtail this curse. This review article blazons some significant development(s) that took place over the period of last decade with regards to its epidemiologic spectrum, characterization of its etiologic agent and important improvement(s)/advancement(s) in its diagnostic as well as prophylactic approach (es). Although, the major achievements to identify and restrict this disease has been carried out in early 80s and 90s, however precarious nature of this organism has largely left scientific and farming community abstruse over its ambit on host specificity and geographic limitation(s). Following strong vaccinal/prophylactic measures, the causative organism(s) further acquired superlative advantages having bypassing host immune surveillance mechanisms acquired through existing vaccine components, besides violating constitutive immunity of host. The plausible reason behind such immunity exclusion is hitherto unknown, when it comes to host's response against pathogen. Resultantly, a detailed study to this effect is highly warranted to avoid further sinister in our poultry operation(s) due to Avibacterium paragallinarum infection. Most of the recent studies endeavoured to work on serovar B of Avibacterium paragallinarum organism which is quite prevalent at the moment at varied places across the globe. This warrants concerted/dedicated diagnostic techniques employing high end bio-molecular approaches for better comprehension of the disease, and to have a blue print with regard to adoption of newer therapeutic strategy towards containment of the infection for fruitful future.